for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Amicus Therapeutics, Inc.

FOLD.O

Latest Trade

9.28USD

Change

-0.00(-0.00%)

Volume

6,650,851

Today's Range

8.98

 - 

9.68

52 Week Range

7.11

 - 

14.62

As of on the NASDAQ ∙ Minimum 15 minute delay

Latest Developments

Amicus Therapeutics Reports Q3 Loss Per Share Of $0.24

Nov 11 (Reuters) - Amicus Therapeutics Inc <FOLD.O>::AMICUS THERAPEUTICS ANNOUNCES THIRD QUARTER 2019 FINANCIAL RESULTS AND CORPORATE UPDATES.Q3 LOSS PER SHARE $0.24.SEES FY 2019 REVENUE $170 MILLION TO $180 MILLION.Q3 EARNINGS PER SHARE ESTIMATE $-0.32 -- REFINITIV IBES DATA.FY2019 REVENUE VIEW $177.3 MILLION -- REFINITIV IBES DATA.REITERATED FY 2019 GUIDANCE.QTRLY GLOBAL REVENUE FOR FABRY PRECISION MEDICINE GALAFOLD $48.8 MILLION.CASH, CASH EQUIVALENTS, AND MARKETABLE SECURITIES TOTALED $514.2 MILLION AT SEPTEMBER 30.EXPECTS TO END 2019 WITH MORE THAN $420 MILLION IN CASH ON HAND.NOW EXPECTS TO END 2019 WITH MORE THAN $420 MILLION IN CASH ON HAND.EXTENDED CASH RUNWAY PROJECTION FROM 2021 TO WELL INTO FIRST HALF OF 2022.Q3 REVENUE VIEW $47.7 MILLION -- REFINITIV IBES DATA.

Amicus Announces Additional Positive Interim Clinical Data For Cln6 Batten Disease Gene Therapy

Oct 24 (Reuters) - Amicus Therapeutics Inc <FOLD.O>::AMICUS ANNOUNCES ADDITIONAL POSITIVE INTERIM CLINICAL DATA FOR CLN6 BATTEN DISEASE GENE THERAPY AT 48TH ANNUAL MEETING OF THE CHILD NEUROLOGY SOCIETY.AMICUS THERAPEUTICS INC - EVIDENCE OF DISEASE STABILIZATION IN 7 OF 8 CHILDREN WITH DATA FOR UP TO 2 YEARS POST-TREATMENT.AMICUS THERAPEUTICS INC - NEW DATA SUPPORT MEANINGFUL IMPACT ON MOTOR AND LANGUAGE FUNCTION IN CHILDREN WITH FATAL NEUROLOGIC DISEASE.

Amicus Therapeutics Says Co Raises Lower End Of FY19 Global Galafold Revenue Guidance To $170 Mln-$180 Mln

Oct 10 (Reuters) - Amicus Therapeutics Inc <FOLD.O>::AMICUS THERAPEUTICS ANNOUNCES PRELIMINARY THIRD QUARTER 2019 REVENUE AND FINANCIAL OUTLOOK AT 2019 ANALYST DAY.AMICUS THERAPEUTICS INC - COMPANY RAISES LOWER END OF FY19 GLOBAL GALAFOLD REVENUE GUIDANCE TO $170 MILLION -$180 MILLION.AMICUS THERAPEUTICS INC - CASH RUNWAY EXTENDED FROM 2021 TO WELL INTO 1H 2022.AMICUS THERAPEUTICS INC - EXPECTS TO RECORD APPROXIMATELY $48 MILLION (PRELIMINARY AND UNAUDITED) IN GALAFOLD REVENUE FOR Q3 2019.AMICUS THERAPEUTICS INC - AMICUS NOW EXPECTS TO END 2019 WITH MORE THAN $420 MILLION IN CASH ON HAND.

Amicus Therapeutics Q2 Loss Per Share $0.36

Aug 8 (Reuters) - Amicus Therapeutics Inc <FOLD.O>::AMICUS THERAPEUTICS ANNOUNCES SECOND QUARTER 2019 FINANCIAL RESULTS AND CORPORATE UPDATES.Q2 LOSS PER SHARE $0.36.Q2 EARNINGS PER SHARE ESTIMATE $-0.33 -- REFINITIV IBES DATA.SEES FY 2019 REVENUE $160 MILLION TO $180 MILLION.Q2 REVENUE $44.1 MILLION VERSUS REFINITIV IBES ESTIMATE OF $41.1 MILLION.REITERATING FY19 REVENUE GUIDANCE OF $160M-$180M.

Amicus Therapeutics, Catalent Biologics Enter Strategic Partnership For Gene Therapy Development And Manufacturing

July 2 (Reuters) - Amicus Therapeutics Inc <FOLD.O>::AMICUS THERAPEUTICS AND CATALENT BIOLOGICS ENTER STRATEGIC PARTNERSHIP FOR GENE THERAPY DEVELOPMENT AND MANUFACTURING.AMICUS THERAPEUTICS INC - ENTERED INTO A STRATEGIC MANUFACTURING AGREEMENT WITH PARAGON GENE THERAPY, A UNIT OF CATALENT BIOLOGICS.AMICUS THERAPEUTICS INC - COLLABORATION INCLUDES MULTIPLE ACTIVE PRECLINICAL LYSOSOMAL DISORDER PROGRAMS.

Amicus Therapeutics And Brammer Bio Enter Gene Therapy Collaboration

July 1 (Reuters) - Amicus Therapeutics Inc <FOLD.O>::AMICUS THERAPEUTICS AND BRAMMER BIO, A PART OF THERMO FISHER SCIENTIFIC, ENTER STRATEGIC GENE THERAPY DEVELOPMENT AND MANUFACTURING COLLABORATION.AMICUS THERAPEUTICS INC - ENTERED INTO A STRATEGIC MANUFACTURING COLLABORATION WITH THERMO FISHER SCIENTIFIC.AMICUS THERAPEUTICS - THERMO FISHER, CO TO DEVELOP PLATFORM MANUFACTURING CAPABILITIES TO SUPPORT BROADER PORTFOLIO OF AAV GENE THERAPY PROGRAMS.

Amicus Therapeutics Prices Underwritten Offering Of Common Stock

May 30 (Reuters) - Amicus Therapeutics Inc <FOLD.O>::AMICUS THERAPEUTICS PRICES UNDERWRITTEN OFFERING OF COMMON STOCK.AMICUS THERAPEUTICS - ANNOUNCED PRICING OF AN UNDERWRITTEN OFFERING OF 16,279,070 SHARES OF ITS COMMON STOCK AT $10.75 PER SHARE.

Amicus Therapeutics Announces $150 Million Underwritten Public Offering Of Its Common Stock

May 29 (Reuters) - Amicus Therapeutics Inc <FOLD.O>::AMICUS THERAPEUTICS ANNOUNCES PUBLIC OFFERING OF COMMON STOCK.AMICUS THERAPEUTICS INC - COMMENCED A $150 MILLION UNDERWRITTEN PUBLIC OFFERING OF ITS COMMON STOCK.

Amicus Therapeutics Q1 Loss Per Share $0.56

May 8 (Reuters) - Amicus Therapeutics Inc <FOLD.O>::AMICUS THERAPEUTICS ANNOUNCES FIRST QUARTER 2019 FINANCIAL RESULTS AND CORPORATE UPDATES.Q1 LOSS PER SHARE $0.56.Q1 REVENUE $34 MILLION VERSUS REFINITIV IBES ESTIMATE OF $37.9 MILLION.Q1 EARNINGS PER SHARE ESTIMATE $-0.31 -- REFINITIV IBES DATA.SEES FY 2019 REVENUE $160 MILLION TO $180 MILLION.SAYS EXPECTS HIGHER REVENUE GROWTH IN SECOND AND FOURTH QUARTERS OF 2019.SAYS COMPANY EXPECTS TO END 2019 WITH APPROXIMATELY $300 MILLION IN CASH ON HAND.

Amicus Therapeutics Inc Files For Potential Mixed Shelf Offering Size Not Disclosed

April 24 (Reuters) - Amicus Therapeutics Inc <FOLD.O>::AMICUS THERAPEUTICS INC FILES FOR POTENTIAL MIXED SHELF OFFERING; SIZE NOT DISCLOSED - SEC FILING.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up